Evidence map›Paper›PMID 35932968›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

Exhaled breath SARS-CoV-2 shedding patterns across variants of concern.

Joren Raymenants, Wout Duthoo, Tim Stakenborg, Bert Verbruggen, Julien Verplanken, Jos Feys, Joost Van Duppen, Rabea Hanifa, Elisabeth Marchal, Andy Lambrechts and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Joren RaymenantsLaboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000, Leuven, Belgium; Department of general internal medicine, University Hospitals Leuven, 3000, Leuven, Belgium. Electronic address: Joren.raymenants@kuleuven.be.
Wout DuthooImec Solutions department, imec, 3001, Leuven, Belgium.
Tim StakenborgLife Science Technologies department, imec, 3001, Leuven, Belgium.
Bert VerbruggenImec Solutions department, imec, 3001, Leuven, Belgium.
Julien VerplankenEnabling Digital Transformations department, imec, 9000, Ghent, Belgium.
Jos FeysDepartment of Clinical and Epidemiological Virology (Rega Institute), 3000, Leuven, Belgium.
Joost Van DuppenLife Science Technologies department, imec, 3001, Leuven, Belgium.
Rabea HanifaLife Science Technologies department, imec, 3001, Leuven, Belgium.
Elisabeth MarchalLife Science Technologies department, imec, 3001, Leuven, Belgium.
Andy LambrechtsImec Solutions department, imec, 3001, Leuven, Belgium.
Piet MaesKU Leuven, 3000, Leuven, Belgium.
Emmanuel AndréLaboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000, Leuven, Belgium; Department of laboratory medicine, University Hospitals Leuven, 3000, Leuven, Belgium.
Nik Van den WijngaertImec Solutions department, imec, 3001, Leuven, Belgium.
Peter PeumansLife Science Technologies department, imec, 3001, Leuven, Belgium.
IMEC · BEVIB-KU Leuven Center for Microbiology · BEKU Leuven · BERega Institute for Medical Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe performed exhaled breath (EB) and nasopharyngeal (NP) quantitative polymerase chain reaction (qPCR) and NP rapid antigen testing (NP RAT) of SARS-CoV-2 infections with different variants.

methodsWe included immuno-naïve alpha-infected (n = 11) and partly boosted omicron-infected patients (n = 8) as high-risk contacts. We compared peak NP and EB qPCR cycle time (ct) values between cohorts (Wilcoxon-Mann-Whitney test). Test positivity was compared for three infection phases using Cochran Q test.

resultsPeak median NP ct was 11.5 (interquartile range [IQR] 10.1-12.1) for alpha and 12.2 (IQR 11.1-15.3) for omicron infections. Peak median EB ct was 25.2 (IQR 24.5-26.9) and 28.3 (IQR 26.4-30.8) for alpha and omicron infections, respectively. Distributions did not differ between cohorts for NP (P = 0.19) or EB (P = 0.09). SARS-CoV-2 shedding peaked on day 1 in EB (confidence interval [CI] 0.0 - 4.5) and day 3 in NP (CI 1.5 - 6.0). EB qPCR positivity equaled NP qPCR positivity on D0-D1 (P = 0.44) and D2-D6 (P = 1.0). It superseded NP RAT positivity on D0-D1 (P = 0.003) and D2-D6 (P = 0.008). It was inferior to both on D7-D10 (P < 0.001).

conclusionPeak EB and nasopharynx shedding were comparable across variants. EB qPCR positivity matched NP qPCR and superseded NP RAT in the first week of infection.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansNasopharynxRespiratory SystemCOVID-19Exhaled breathSARS-CoV-2Variants of concernViral shedding

Identifiers

PMID35932968
PMCPMC9349369
OpenAlexW4289839300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.